Compare Credo Technology Group Holding Ltd (CRDO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs GeneDx Holdings Corp — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Credo Technology Group Holding Ltd is far larger — about 19.7× GeneDx Holdings Corp's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and GeneDx Holdings Corp for 19 Days on average.
| CRDO | WGS | |
|---|---|---|
Market Cap | $39.82B | $2.02B |
Volume | 9,451,558 | 734,640 |
Sector | Technology | Health |
52-Week High | $302.52 | $167.51 |
52-Week Low | $87.81 | $34.51 |
Typical Hold Time | 22 Days | 19 Days |
Enterprise Value | $39.08B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $211.86, down 3.7% on the day but maintains strong technical momentum with bullish moving averages and key support at $204. The company demonstrates exceptional growth with 114.7% YoY revenue expansion and 33.83% net margins, though valuation multiples remain elevated at P/E of 74.6. Recent earnings beats and analyst consensus of $267.33 price target suggest continued upside potential despite insider selling activity.
Outlook remains positive driven by AI infrastructure demand and optical technology expansion, with management targeting 85%+ revenue growth. Key risks include premium valuation, customer concentration, and execution challenges as the company scales. The stock offers growth exposure to high-speed connectivity solutions but requires monitoring of margin trends and competitive dynamics.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
